Side Effects of Medrol Dosepak (Methylprednisolone)
The Medrol Dosepak carries significant risks including immunosuppression with increased infection susceptibility, metabolic disturbances (hyperglycemia, weight gain), psychiatric effects, and potential for serious complications like osteonecrosis, though most adverse effects from short courses are manageable and reversible. 1
Infection-Related Risks
The FDA label explicitly warns that methylprednisolone suppresses the immune system and increases infection risk with any pathogen (viral, bacterial, fungal, protozoan, or helminthic). 1 Key infection concerns include:
- Reactivation of latent infections: Tuberculosis, hepatitis B, herpes zoster, and amebiasis can reactivate
- Varicella and measles: Can have serious or fatal courses in non-immune patients taking corticosteroids
- Strongyloides: May cause hyperinfection syndrome with potentially fatal gram-negative septicemia
- Fungal infections: May be exacerbated; avoid use in active systemic fungal infections 1
The rate of infectious complications increases with higher dosages. 1
Metabolic and Endocrine Effects
Hyperglycemia is the most frequently reported complication in clinical practice. 2, 3 In one study of sudden hearing loss treatment, hyperglycemia occurred with large intravenous methylprednisolone doses. 2
Weight gain is consistently reported as a major patient concern and common side effect:
- Patients rank weight gain as the 4th most worrisome adverse effect (clinicians rank it 6th) 4
- In social media analysis, weight gain was the most commonly reported side effect among prednisone users 4
- Studies show mean weight gain ranging from no change to 5 kg over 1-2 years with corticosteroid treatment 4
Musculoskeletal Complications
Osteonecrosis represents a serious concern, particularly with the Medrol Dosepak:
- In a survey of sports medicine physicians, 8.5% of prescribers reported seeing 101 total cases of osteonecrosis (predominantly in the hip) 5
- Among non-prescribing physicians, 25% had seen 500 cases of osteonecrosis, with fear of osteonecrosis being the top reason (30%) for not prescribing 5
- Risk increases in patients with preexisting bone/joint problems, systemic lupus erythematosus, or rheumatoid arthritis 2
Osteoporosis develops with long-term use and is a recognized comorbidity that increases risk of glucocorticoid-related adverse events. 6, 7
Psychiatric and Neurologic Effects
Psychic derangements may appear ranging from euphoria, insomnia, mood swings, personality changes, and severe depression to frank psychotic manifestations. 1 Existing emotional instability or psychotic tendencies may be aggravated. 1
The 2019 ASH guidelines emphasize monitoring for sleep and mood disturbances as part of routine corticosteroid safety surveillance. 3
Ophthalmologic Effects
Prolonged use produces:
- Posterior subcapsular cataracts
- Glaucoma with possible optic nerve damage
- Enhanced risk of secondary ocular infections 1
Patients with glaucoma represent a high-risk group requiring lower initial doses. 6
Cardiovascular and Gastrointestinal Effects
Hypertension is a recognized comorbidity associated with increased risk of glucocorticoid-related side effects. 6 Female patients with difficult-to-control hypertension may benefit from alternative formulations (e.g., intramuscular methylprednisolone). 6
Gastrointestinal effects include:
- Peptic ulcer risk (particularly with NSAID co-medication) 6
- Risk in nonspecific ulcerative colitis, diverticulitis, or active peptic ulcer 1
- Pancreatitis (short-term use) 7
Dosing Context and Risk Mitigation
The standard Medrol Dosepak is significantly underdosed for many conditions. The pack contains 4-mg tablets providing only 84 mg total over 6 days, equivalent to 105 mg prednisone—compared to 540 mg prednisone over 14 days for adequate treatment of conditions like sudden hearing loss. 2
Risk Factors Requiring Dose Adjustment
Higher-risk patients requiring lower doses include those with: 6
- Diabetes or glucose intolerance
- Osteoporosis or recent fractures
- Hypertension
- Glaucoma or cataracts
- Cardiovascular disease
- Female sex (associated with higher adverse event rates)
- Concurrent NSAID use
Short-Term vs. Long-Term Effects
Short-term use (≤6 weeks) is associated with generally mild, manageable side effects including cutaneous effects, electrolyte abnormalities, hyperglycemia, and neuropsychiatric effects. 3, 7 The 2019 ASH guidelines strongly recommend against corticosteroid courses >6 weeks due to lack of additional benefit and known complications. 3
Long-term use carries more serious risks: osteoporosis, aseptic joint necrosis, adrenal insufficiency, hepatic effects, hyperlipidemia, growth suppression in children, and possible congenital malformations. 7
Special Populations
Pregnancy: Methylprednisolone administration before 10 weeks gestation may slightly increase cleft palate risk, though data are conflicting. Use with caution in first trimester. 8
Malignancy: Tumor lysis syndrome has been reported in patients with hematological malignancies and solid tumors. Monitor high-risk patients closely. 1
Kaposi's sarcoma has been reported with corticosteroid therapy, most often for chronic conditions. 1
Recent Safety Data
A 2025 multicenter study of 930 TKA patients found no significant increase in 90-day periprosthetic joint infection (0.7% vs 0%), surgical site infection, or wound complications with methylprednisolone taper versus controls. 9 A 2024 shoulder arthroplasty RCT reported only 1 infection in controls and 1 cubital tunnel syndrome in the treatment group at mean 21-month follow-up. 10